Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder
Psyence BioMed dosed the first patient in its Phase IIb trial evaluating NPX-5 for the treatment of Adjustment Disorder in cancer patients. The randomized, double-blind study will assess a 25mg dose of nature-derived psilocybin across five clinical sites in Australia.
Key figures
- Drug Name
- NPX-5 (25mg of nature-derived psilocybin)
- Phase Of Trial
- Phase IIb
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.